FDA Inspection 1051249 — Mayinglong Pharmaceutical Group Co., Ltd.
The FDA completed an inspection of Mayinglong Pharmaceutical Group Co., Ltd. on April 13, 2018 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 13, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)